Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Slides:

Advertisements

Similar presentations

Atrial Fibrillation Stroke Prevention with Oral Anticoagulants Why is there discordance between guideline committees & specialists when the data is based.

Advertisements

The GARFIELD Registry is funded by an unrestricted research grant from Bayer Pharma AG Closing Remarks Jean-Pierre Bassand, MD, FESC,

Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.

The GM AHSN AF Landscape Tool: A shared public data platform to promote quality improvements and identify opportunities to prevent AF-related stroke in.

Identifying patients with atrial fibrillation and "truly low" thromboembolic risk who are poorly characterized by CHA2DS2-VASc: Superior performance of.

Addressing the Challenges in Primary and Secondary Stroke Prevention

Anticoagulation in Atrial Fibrillation

Covering the Bases in Cardioversion

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

Silent No More:.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Monitoring Continuum ISSUE-3 Atrial Fibrillation Classification.

Atrial Fibrillation and PCI

NOACs In Long-term VTE Treatment: A State Of The Art Review

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Access to NOAC Therapy:

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

Atrial Fibrillation Project, SSNAP July to September 2013 and QOF Indicators 2012/2013 Guildford and Waverley CCG.

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Nat. Rev. Cardiol. doi: /nrcardio

Educational Event 23rd & 24th January 2013

Up to Date on Which NOAC for Which Patient

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Oral Anticoagulants in AFa,b A Brief History.

Selecting NOACs for High-Risk Patients

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

How to Adjust Anticoagulant Dosing

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

The Essentials for Secondary Stroke Prevention

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Efficacy and Safety of Edoxaban in Patients With AF and HF

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

Adherence in SPAF: Measures to Improve Care

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Atrial Fibrillation.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Identifying High-Risk AF Patients

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotic Therapy in Vascular Protection: From CAD to HF

NOAC Studies in VTE AF Studies Superior Outcomes.

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in patients with atrial fibrillation: the Swedish Atrial Fibrillation.

Program Goals Background: Anticoagulation in Patients With VTE.

Disease Burden of VTE Phases of VTE Treatment.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

5 Good Minutes on Atrial Fibrillation-related Stroke

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

How to Adjust Anticoagulant Dosing

Real-World Data in Cardiology: Focus on Atrial Fibrillation

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

Figure 8. Stroke prevention strategy in patients with AF

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Treating Pulmonary Embolism Today

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Learning Objectives

The Burden Of Atrial Fibrillation

Prevalence of AF Is Substantial and Expected to Grow

Atrial Fibrillation And Stroke

ROCKET-AF Stroke Risk in Paroxysmal AF

CHA2DS2-VASc Risk of Stroke in Patients With AF

GARFIELD-AF Increasing CHA2DS2-VASc Score Predicts Poor Outcomes

GARFIELD-AF Increasing HAS-BLED Score Predicts Poor Outcomes

AHA/ACC/HRS Guidelines Anticoagulation Recommendations for Patients With Nonvalvular AF

ORBIT-AF Physician Assessment of Stroke Risk vs CHADS2 Score

GARFIELD-AF Evolving Antithrombotic Treatment Patterns

GARFIELD-AF Global Patterns in NOAC Uptake

GARFIELD-AF Event Rates According to Renal Function*

ORBIT-AF Causes of Hospitalization

GARFIELD-AF Reasons for Not Providing VKA*

Registry of the Canadian Stroke Network Most High-Risk Patients With AF Who Have a Stroke Were Not Receiving Guideline-Recommended Therapy

Anticoagulant Use Reduces Stroke Risk in Patients With AF

GARFIELD-AF Event Rates According to TTR

Challenges in AF-Related Stroke Management

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)